CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer pa ...
Taipei, Taiwan
Breast cancer (BC), especially premenopausal, is emerging rapidly in East Asia in recent 20 years. Half of the breast cancer...
Phase 2
Taipei, Taiwan
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Taipei, Taiwan and 71 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Taipei, Taiwan and 145 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Taipei, Taiwan and 317 other locations
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other ther ...
Phase 1
Taipei, Taiwan and 36 other locations
ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical pra...
Phase 3
Taipei, Taiwan and 65 other locations
in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast...
Phase 1, Phase 2
Taipei, Taiwan and 31 other locations
Olaparib, a PARP inhibitor, is proven as an effective therapy for germline BRCA1/2-mutated breast cancer; however, the therapeutic ...
Phase 2
Taipei, Please Select, Taiwan and 2 other locations
with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of...
Phase 3
Taipei, Taiwan and 166 other locations
Clinical trials
Research sites
Resources
Legal